This study tests a drug called iptacopan to see how well it works, how safe it is, and how easy it is to take. The study is for people with two kidney diseases: C3 Glomerulopathy (C3G) and Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN). In this study, everyone will know they are taking iptacopan, which is called open-label. The study will last until the medicine is available to buy or up to 66 months. Participants must have completed a previous related study.
- The study might last up to about 5.5 years (66 months).
- You must have been in a previous study to join.
- People with certain health issues or infections cannot join.